Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,406
datasets available to search
ShareScore release 0.9.0
Dataset results
1,406 results for “Migraine”
Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine
ClinicalTrials.gov study NCT03398668. IPD Sharing: NO. Countries: 1. Publications: 1.
HD-EEG Connectivity Changes in Migraine Patients Undergoing Treatment With Anti-CGRP mAbs
ClinicalTrials.gov study NCT06155123. IPD Sharing: Not stated. Countries: 1. Publications: 8.
Saline Injections for Prophylactic Treatment of Chronic Migraine
ClinicalTrials.gov study NCT03919045. IPD Sharing: NO. Countries: 1. Publications: 6.
Intravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack
ClinicalTrials.gov study NCT01730326. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Validation of a Questionnaire for Allodynia in Migraine.
ClinicalTrials.gov study NCT04580641. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Treximet in Acute Migraine Headache: Assessing Cognitive Function
ClinicalTrials.gov study NCT00837044. IPD Sharing: Not stated. Countries: 1. Publications: 10.
Nasal Cavity Cooling for the Symptomatic Relief of Migraine Headache - a Pilot Study
ClinicalTrials.gov study NCT04660864. IPD Sharing: NO. Countries: 1. Publications: 2.
Vagal Nerve Stimulation and Pain Frequency, Intensity in Chronic Migraine
ClinicalTrials.gov study NCT06191016. IPD Sharing: NO. Countries: 1. Publications: 4.
Adrenomedullin induces migraine-like attacks in patients with migraine without aura
Open the record for dataset details and reuse information.
Data from: Gray matter volume modifications in migraine: a cross-sectional and longitudinal study
Open the record for dataset details and reuse information.
Appendix: Association between hemostatic profile and migraine: a Mendelian randomization analysis
Open the record for dataset details and reuse information.
One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study - supplementary data
<p><b>Objective:</b> To assess efficacy and tolerability of 1-year erenumab treatment in patients with episodic migraine. </p> <p><b>Methods: </b>Patients were randomized (<i>n</i>=955; 1:1:1) during the 24-week double-blind treatment phase (DBTP) to monthly subcutaneous placebo, erenumab 70 or 140mg. At Week 24, 845 patients were re-randomized (1:1) to erenumab 70 or 140mg during the 28-week dose-blinded active-treatment phase (ATP). Monthly migraine days (MMD), achieving ≥50%, ≥75% and 100% reduction in MMD, and safety/tolerability were assessed. </p> <p><b>Results: </b>Mean MMD at DBTP baseline was 8.3. At Week 52, mean changes (SE) from pre-DBTP baseline/Week 24 (pre-ATP baseline) in MMD were −4.2 (0.2)/−1.1 (0.2) (70mg) and −4.6 (0.2)/−1.8 (0.2) (140mg) irrespective of treatment during the DBTP. For patients reducing dose from 140 (DBTP) to 70mg (ATP), change in MMD from Week 24 to 52 was −0.1 (0.3), and for those increasing from 70 (DBTP) to 140mg (ATP) was −1.8 (0.3). At Week 52, 61.0%, 38.5% and 19.8% of patients on erenumab 70mg, and 64.9%, 40.8% and 21.2% on erenumab 140mg, achieved ≥50%, ≥75% and 100% reduction in MMD from DBTP baseline, respectively. Among erenumab-treated patients in DBTP who showed ≥50% reduction in MMD during the last 3 months of DBTP and completed ATP, 86% showed sustained responses at ≥50% during the last 3 months of ATP. Safety of erenumab in the ATP was similar to the DBTP; exposure-adjusted incidence rates of adverse events were similar for either dose.</p> <p><b>Conclusion: </b>Over 52 weeks, erenumab provided sustained efficacy in episodic migraine; the safety profiles were similar between erenumab dose groups in the presence of dose blinding. </p>
Data from: Lasmiditan is an effective acute treatment for migraine A phase 3 randomized study
Objective: To assess the efficacy and safety of lasmiditan in the acute treatment of migraine. Methods: Adult patients with migraine were randomized (1:1:1) to a double-blind dose of oral lasmiditan 200 mg, lasmiditan 100 mg, or placebo, and were asked to treat their next migraine attack within 4 hours of onset. Over 48 hours following dosing, patients used an electronic diary to record headache pain, and also the presence of nausea, phonophobia, and photophobia, one of which was designated their most bothersome symptom (MBS). Results: Of the 1,856 patients who treated an attack, 77.9% had ≥1 cardiovascular risk factor in addition to migraine. Compared with placebo, more patients dosed with lasmiditan 200 mg were free from headache pain at 2 hours after dosing (32.2% vs 15.3%; odds ratio [95% confidence interval]: 2.6 [2.0, 3.6]; p<0.001); and similarly for lasmiditan 100 mg (28.2%; 2.2 [1.6, 3.0]; p<0.001). Furthermore, compared with placebo, more patients dosed with lasmiditan 200 mg (40.7% vs 29.5%; 1.6 [1.3, 2.1]; p<0.001), and lasmiditan 100 mg (40.9%; 1.7 [1.3, 2.2]; p<0.001), were free from their MBS at 2 hours after dosing. Adverse events were mostly mild or moderate in intensity. Conclusions: Lasmiditan, dosed at 200 mg and 100 mg, was efficacious and well tolerated in the treatment of acute migraine among patients with a high level of cardiovascular risk factors.
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
ClinicalTrials.gov study NCT06625060. IPD Sharing: YES. Countries: 14. Publications: 0.
Vagus Nerve Stimulation and Stress Reduction Training for Migraine
ClinicalTrials.gov study NCT03592329. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Migraine Treatment With Nerivio Migra Neurostimulation Device
ClinicalTrials.gov study NCT03076515. IPD Sharing: NO. Countries: 2. Publications: 0.
Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)
ClinicalTrials.gov study NCT04068051. IPD Sharing: NO. Countries: 1. Publications: 0.
Prospective Survey of Menstrual Migraine & Prevention With Eletriptan
ClinicalTrials.gov study NCT00259649. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department
ClinicalTrials.gov study NCT02972502. IPD Sharing: NO. Countries: 1. Publications: 0.
Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE
ClinicalTrials.gov study NCT01775735. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.